Comme lors de l'exercice précédent, Proxinvest regrette que la société maintienne la possibilité de l'usage des autorisations d'augmentation du capital en période d'offre publique, ce qui nous conduit à recommander l'opposition aux résolutions 10 à 12, 14 et 15. Par ailleurs, les montants proposés dans ces résolutions ainsi que dans les résolutions 19 à 23 sont excessifs.
Proxinvest regrette également le manque de communication concernant les rémunérations des dirigeants. De plus, la société empêche les actionnaires de se prononcer sur la rémunération en ne soumettant pas au vote de résolution à ce sujet.
Il est à noter que la société ne respecte le taux de féminisation définie par la loi Copé-Zimmermann. En effet la société possède un taux de féminisation de 13%. La société n'est pas soumise à cette loi puisque la société évolue sur le marché d'Euronext Growth.
Cellectis is a gene-editing company employing its core proprietary technologies to develop products in the field of immuno-oncology. UCART19 is Co.'s lead product. UCART19 is an engineered T-cell product which drives its ability to target and kill CD19-bearing cells, such as B-cell malignancies. Co. is also developing wholly-owned product candidates UCART123, UCARTCS1 and UCART38, which are in various stages of development. UCART 123, UCARTCS1 and UCART38 are engineered T-cell products that bear CARs that seek to kill cells expressing targets CD123, CS1 and CD38, respectively, which are found in other hematologic tumors, such as acute myeloid leukemia, or AML, and multiple myeloma, or MM.
Founded in 1995, Proxinvest is an independent proxy firm supporting the engagement and proxy analysis processes of investors. Proxinvest mission is to analyse corporate governance practices and resolutions proposed at general meetings of listed firms.
Proxinvest main services are :
Proxinvest has been a pioneer and champion of good corporate governance and has grown into a recognised expert in the field.
Proxinvest is independently-owned and only works for investors : Proxinvest does not provide consulting services to the companies it covers, mitigating related risks to its clients and ensuring the independence of our analysis. As a result Proxinvest is able to take a robust, independent, engaged and unconflicted view of the companies in which our clients invest.
As Managing Partner of Expert Corprate Governance Service Ltd (ECGS), Proxinvest has built a large network of corporate governance experts to support clients in corporate governance analysis worldwide.
A director at Cellectis sold 105,528 shares at 7.997USD and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of board mem...
>Amendment to its licence agreement with Servier - Cellectis has just announced an amendment to its initial agreement with Servier. This will allow Servier to obtain an exclusive worldwide license for the development and subsequent marketing of all products targeting CD19 (including ALLO-501A). In parallel, Cellectis will regain control over its five developments initially licensed to Servier but for which the targets had never been disclosed. On the financial s...
Résolutions 8 et 10 relativement aux rémunérations 2019 de Monsieur Philippe Rosio, Président Directeur Général et de Madame Arline Gaujal-Kempler, Directeur Général Délégué: Selon la société, les résolutions consistent au fait d’approuver l’absence de toute rémunération perçue par les dirigeants au sein de la société. Cependant, ceux-ci sont rémunérés par le biais de la société GEST qui facture à Foncière Inéa des prestations de management et de gestion administrative pour un montant de 4 138 000 €, soit 13,3% des loyers nets et 10% du résultat net part du groupe (résolution 5). Ainsi, bien q...
General: The AGM is to be held in the form of a virtual AGM in accordance with the German Law to Mitigate the Consequences of the COVID-19 Pandemic. The physical presence of shareholders or their authorised proxies is not possible. The voting rights may therefore be exercised solely by postal vote or by granting authority to the proxies designated by the Company. One of the major shareholders, Roland Oetker, is the former President and since 2008 the Honorary President of DSW, the local partner of ECGS. This report has been prepared using standard ECGS guidelines. Evotec was founded 19...
In general, Danske Bank is in compliance with the Danish regulations relating to organisation and procedures of the Annual General Meeting. Under ITEM 4f it is proposed to re-appoint Ms. Carol Sergeant as Vice Chairman of the board of directors. Although she is considered independent, ECGS does NOT approve of the re-appointment of any board members who were part of the board of directors at the time of the money laundering scandal in Estonia. Accordingly, ECGS recommends to vote OPPOSE. Under ITEM 7 authorisation is sought to repurchase own shares. Although the authority requested woul...
Unfortunately, this report is not available for the investor type or country you selected.Browse all ResearchPool reports
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.